Donatello Gasparro

Parma, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Testicular metastasis of prostate adenocarcinoma: the other side of orchiepididymitis.

Testicular metastasis of prostate adenocarcinoma: the other side of orchiepididymitis.

Journal: Pathologica

Published: October 23, 2023

High Prognostic Value of 68Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry.

High Prognostic Value of 68Ga-PSMA PET/CT in Renal Cell Carcinoma and Association with PSMA Expression Assessed by Immunohistochemistry.

Journal: Diagnostics (Basel, Switzerland)

Published: August 02, 2023

Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies.

Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies.

Journal: British journal of cancer

Published: February 24, 2023

Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.

Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.

Journal: Chinese clinical oncology

Published: February 14, 2023

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.

Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature.

Journal: Cancers

Published: September 15, 2021

Metastatic Clear Cell Renal Cell Carcinoma: The Great Pretender and the Great Dilemma.

Metastatic Clear Cell Renal Cell Carcinoma: The Great Pretender and the Great Dilemma.

Journal: World journal of oncology

Published: August 13, 2021

18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.

18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.

Journal: Clinical nuclear medicine

Published: August 10, 2021

Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.

Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study.

Journal: ESMO open

Published: July 30, 2021

Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.

Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 21, 2021

Synergic role of dual tracer PET/CT with 18F-FDG and 68Ga-PSMA in the detection of papillary renal cell carcinoma recurrence.

Synergic role of dual tracer PET/CT with 18F-FDG and 68Ga-PSMA in the detection of papillary renal cell carcinoma recurrence.

Journal: Revista espanola de medicina nuclear e imagen molecular

Published: January 31, 2021

[68Ga]Ga-PSMA-HBED-CC PET/CT demonstrates to be superior to ceCT in detecting early treatment response in metastatic clear cell renal cell carcinoma.

[68Ga]Ga-PSMA-HBED-CC PET/CT demonstrates to be superior to ceCT in detecting early treatment response in metastatic clear cell renal cell carcinoma.

Journal: European journal of nuclear medicine and molecular imaging

Published: December 30, 2020

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE.

Effects of abiraterone acetate plus prednisone on bone turnover markers in chemotherapy-naïve mCRPC patients after ADT failure: A prospective analysis of the italian real-world study ABITUDE.

Journal: Journal of bone oncology

Published: July 21, 2020

Showing 1-12 of 28

Last Updated: 09/26/2026